in-PharmaTechnologist.com presents its round-up of executive moves within the pharma sector, including appointments from Unilife, Aceto and Cangene.
Unilife has expanded its management team to support business growth with three new additions.
Jack Kelley, Michael Ratigan and Ian Hanson will all take on senior roles to support Unilife in the progressive launch of the Unifill ready-to-fill (prefilled) syringe to a number of pharmaceutical and biotechnology companies.
Kelly, whose 15-year career includes Medtronic, JP Morgan and Becton Dickinson, will take on the role of vice president of strategic marketing.
Formerly the director of self administration of injectable systems (SAIS) at BD, Ratigan comes to Uniflife as VP of commercial development.
Meanwhile new director of advanced drug delivery systems Hanson moved from Medtronic Diabetes, where he served as the senior engineering manager and the leader of advanced engineering and systems department.
"The group of talented industry leaders that recently joined our team have strong backgrounds in the design, commercialization and sale of advanced drug delivery systems, further bolstering our existing capabilities and supporting our growth," stated Mr. Alan Shortall, CEO of Unilife.
Aceto has named Nicholas Shackley international senior vice president of active pharmaceutical ingredients (APIs).
With 25 years industry experience, Shakley most recently held P&L responsibility with BASF for their pharmaceutical ingredients and service business unit as VP-North America.
Albert Eilender, chairman and CEO of Aceto said: "With our focus on accelerating growth in supplying quality ingredients for the pharmaceutical market on an international basis, we are delighted to have Nick join the Company in this leadership role.”
Clinical stage biopharma company Tranzyme Pharma has filled two newly created positions with David Moore and Kenneth Reuttimann.
Moore will join the team as VP, commercial operations, and will be responsible for designing and executing the Company’s global product strategy for Phase III intravenous ghrelin agonist ulimorelin (TZP-101).
Ruettimann is the new senior director manufacturing operations. He will manage the chemical and pharmaceutical development strategies for the company’s drug candidates.
Of the expansion, Vipin Garg, president and CEO of Tranzym, said: “We are pleased with our progress and remain dedicated to bringing safe and effective treatments for underserved GI motility disorders to the market.”
InSite Vision has appointed Brian Levy to its board of directors.
Levy is currently the Chief Scientific Officer of Nexis Vision, which is developing a novel refractive surgery technology, as well as clinical professor of ophthalmology at the University of Rochester in New York.
Timothy Ruane, CEO of InSite, said: “Brian's 30-plus years of experience in developing treatments for unmet ophthalmic patient needs and his proven leadership in companies large and small will be a wonderful addition to our Board as we aggressively advance our pipeline of late-stage products through Phase 3 clinical development.”
Percival Barretto-Ko is the new senior VP of corporate strategy and government affairs at Astellas .
Barret-Ko is the first to take the newly created position for the company, after moving from the role of executive director, corporate strategy and communications at Astellas Pharma Europe.
Astellas president and CEO Masao Yoshida said: "This realignment brings key strategic functions closer together at the corporate level.
“Percival has an outstanding track record both in the pharmaceutical industry and at Astellas' European operations. He will be a great addition to our senior management team."
Cangene Corporation’s board of directors has unanimously appointed John Sedor as president and CEO.
Sedor, who was recently president, CEO and director of CPEX Pharmaceuticals, will also serve on the biopharma’s board as a director.
He said: "I'm very pleased to join Cangene, a pioneering company with solid fundamentals, including successful biodefence and biopharma products, a strong balance sheet and talented people.
“Over the next few months, I intend to conduct a comprehensive, top-to-bottom review of the business and develop a plan to accelerate growth and enhance shareholder value at Cangene.
“I believe this Company has significant value-creation potential and intend to drive it to achieve that potential over the long-term."
Packaging company Sapient, a subsidiary of MDCI, has named William Fabricino as Midwest Sales Manager.
Fabricino was sales manager for Warehouse Systems, Warehouse Equipment, and Kingway Caps.